Status:
RECRUITING
Local vs Systemic Methotrexate in Management of Uterine Ectopic Pregnancy
Lead Sponsor:
Tanta University
Conditions:
Local
Systemic
Eligibility:
FEMALE
20-40 years
Phase:
NA
Brief Summary
This study aims to compare local and systemic methotrexate in the management of uterine ectopic pregnancy regarding the duration of beta human chorionic gonadotropin (hCG) clearance and need for furth...
Detailed Description
Ectopic pregnancy is considered a life-threatening condition which requires immediate intervention. Owing to the advancements in medical technology, ectopic pregnancy can now be diagnosed in the early...
Eligibility Criteria
Inclusion
- Age from 20 to 40 years.
- Women with uterine ectopic pregnancy (interstitial pregnancy, cervical pregnancy, or cesarean scar pregnancy).
- Gestational age is less than 9 weeks, the embryo size is smaller than 10 mm, and the serum beta-human chorionic gonadotropin (β-hCG) levels are less than 10,000 mIU/mL.
Exclusion
- Patients with basal beta hCG levels less than 1500 mIU/Ml.
- Any contraindications to MTX as a hepatic disorder, renal disorder and thrombocytopenia
- Diabetes mellitus.
- Severe vaginal bleeding or hemodynamic changes or hemoperitoneum.
- History of cancer.
- Ascites.
- Pleural effusion.
Key Trial Info
Start Date :
August 15 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
July 1 2025
Estimated Enrollment :
34 Patients enrolled
Trial Details
Trial ID
NCT06554470
Start Date
August 15 2024
End Date
July 1 2025
Last Update
August 16 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Tanta University
Tanta, El-Gharbia, Egypt, 31527